This issue of Interventional Cardiology Clinics, edited by Drs. Dominick Angiolillo and Matthew Price, will focus on Antiplatelet and Anticoagulation Therapy in PCI. The topics covered in this volume will span across pretreatment with antiplatelet agents; optimal duration of antiplatelet therapy after PCI; Cangrelor and its role in percutaneous coronary intervention; Ticagrelor and its effects beyond the P2Y12 receptor; dyspnea and Reversibly-binding P2Y12 antagonists; PAR receptor inhibition post-PCI; switching P2Y12 receptor inhibiting therapies; antiplatelet and antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting; antithrombotic therapy to reduce ischemic events in ACS patients undergoing PCI; and the current role of platelet function testing in PCI and CABG, among other topics.
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Forthcoming Issues - p. ix 7. Preface - p. xi 8. Regulation of Platelet Activation and Coagulation and Its Role in Vascular Injury and Arterial Thrombosis - p. 1 9. Pretreatment with Antiplatelet Agents in the Setting of Percutaneous Coronary Intervention: When and Which Drugs? - p. 13 10. Optimal Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - p. 25 11. Cangrelor: Pharmacology, Clinical Data, and Role in Percutaneous Coronary Intervention - p. 39 12. Ticagrelor: Effects Beyond the P2Y12 Receptor - p. 49 13. Protease-Activated Receptor-1 Antagonists Post-Percutaneous Coronary Intervention - p. 57 14. Switching P2Y12 Receptor Inhibiting Therapies - p. 67 15. Antiplatelet and Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Coronary Stenting - p. 91 16. Antiplatelet Therapy for Secondary Prevention After Acute Myocardial Infarction - p. 119 17. Antithrombotic Therapy to Reduce Ischemic Events in Acute Coronary Syndromes Patients Undergoing Percutaneous Coronary Intervention - p. 131 18. Genetic Determinants of P2Y12 Inhibitors and Clinical Implications - p. 141 19. Current Role of Platelet Function Testing in Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting - p. 151
No hay muestra disponible
No hay ficha técnica disponible
This issue of Interventional Cardiology Clinics, edited by Drs. Dominick Angiolillo and Matthew Price, will focus on Antiplatelet and Anticoagulation Therapy in PCI. The topics covered in this volume will span across pretreatment with antiplatelet agents; optimal duration of antiplatelet therapy after PCI; Cangrelor and its role in percutaneous coronary intervention; Ticagrelor and its effects beyond the P2Y12 receptor; dyspnea and Reversibly-binding P2Y12 antagonists; PAR receptor inhibition post-PCI; switching P2Y12 receptor inhibiting therapies; antiplatelet and antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting; antithrombotic therapy to reduce ischemic events in ACS patients undergoing PCI; and the current role of platelet function testing in PCI and CABG, among other topics.
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Forthcoming Issues - p. ix 7. Preface - p. xi 8. Regulation of Platelet Activation and Coagulation and Its Role in Vascular Injury and Arterial Thrombosis - p. 1 9. Pretreatment with Antiplatelet Agents in the Setting of Percutaneous Coronary Intervention: When and Which Drugs? - p. 13 10. Optimal Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - p. 25 11. Cangrelor: Pharmacology, Clinical Data, and Role in Percutaneous Coronary Intervention - p. 39 12. Ticagrelor: Effects Beyond the P2Y12 Receptor - p. 49 13. Protease-Activated Receptor-1 Antagonists Post-Percutaneous Coronary Intervention - p. 57 14. Switching P2Y12 Receptor Inhibiting Therapies - p. 67 15. Antiplatelet and Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Coronary Stenting - p. 91 16. Antiplatelet Therapy for Secondary Prevention After Acute Myocardial Infarction - p. 119 17. Antithrombotic Therapy to Reduce Ischemic Events in Acute Coronary Syndromes Patients Undergoing Percutaneous Coronary Intervention - p. 131 18. Genetic Determinants of P2Y12 Inhibitors and Clinical Implications - p. 141 19. Current Role of Platelet Function Testing in Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting - p. 151
No hay muestra disponible
No hay ficha técnica disponible
